Prognostic factors for melanoma progression and metastasis: From Hematoxylin-Eosin to genetics

Romanian Journal of Morphology and Embryology

Volumn 53, Issue 3, 2012, Pages 449-459

  Fernandez Flores, Angel ^a  

^a HOSPITAL EL BIERZO   (Spain)

Author keywords

AJCC; Breslow; Clark; Melanoma; Metastases; Mitoses

Indexed keywords

EID: 84866981536     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma, J Clin Oncol, 2001, 19(16):3635-3648.
2. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. An evidence-based staging system for cutaneous melanoma, CA Cancer J Clin, 2004, 54(3):131-149; quiz 182-184.
3. Shuman AG, Light E, Olsen SH, Pynnonen MA, Taylor JM, Johnson TM, Bradford CR. Mucosal melanoma of the head and neck: predictors of prognosis, Arch Otolaryngol Head Neck Surg, 2011, 137(4):331-337.
4. LeBoit PE, Burg G, Weedon D, Sarasin A, Chapter 2: Melanocytic tumors. In: LeBoit PE, Burg G, Weedon D, Sarasin A (eds). Pathology and genetics of skin tumours, World Health Organization Classification of Tumours, IARC Press, Lyon, 2006.
5. Clark WH Jr. A classification of malignant melanoma in man correlated with histogenesis and biologic behavior, Adv Biol Skin, 1967, 8:621-647.
6. Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care, Mol Oncol, 2011, 5(2): 124-136.
7. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin, Cancer Res, 1969, 29(3):705-727.
8. McGovern VJ. The classification of melanoma and its relationship with prognosis, Pathology, 1970, 2(2):85-98.
9. Mihm MC Jr, Clark WH Jr, From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas, N Engl J Med, 1971, 284(19):1078-1082.
10. Egberts F, Momkvist A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A. Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma >or=1 mm, Tumour Biol, 2010, 31(1): 8-15.
11. Crowson AN, Magro CM, Mihm MC. Prognosticators of melanoma, the melanoma report, and the sentinel lymph node, Mod Pathol, 2006, 19(Suppl 2):S71-S87.
12. Murali R, Shaw HM, Lai K, McCarthy SW, Quinn MJ, Stretch JR, Thompson JF, Scolyer RA. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients, Cancer, 2010, 116(17):4130-4138.
13. Livestro DP, Muzikansky A, Kaine EM, Flotte TJ, Sober AJ, Mihm MC Jr, Michaelson JS, Cosimi AB, Tanabe KK. Biology of desmoplastic melanoma: a case-control comparison with other melanomas, J Clin Oncol, 2005, 23(27):6739-6746.
14. Maurichi A, Miceli R, Camerini T, Contiero P, Patuzzo R, Tragni G, Crippa F, Romanidis K, Ruggeri R, Carbone A, Santinami M. Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior, Ann Surg, 2010, 252(6): 1052-1057.
15. Chen JY, Hruby G, Scolyer RA, Murali R, Hong A, Fitzgerald P, Pham TT, Quinn MJ, Thompson JF. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases, Cancer, 2008, 113(10):2770-2778.
16. Scolyer RA, Prieto VG. Melanoma pathology: important issues for clinicians involved in the multidisciplinary care of melanoma patients, Surg Oncol Clin N Am, 2011, 20(1):19-37.
17. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma, Ann Surg, 1970, 172(5):902-908.
18. Elder DE. Thin melanoma, Arch Pathol Lab Med, 2011, 135(3):342-346.
19. Doumas A, Dionyssopoulos A, Christoforidis T, Papaconstantinou A, Efstratiou I, Iakovou I, Lo-Presti D, Georga S, Nikos V, Karatzas N. Is 0.75 mm Breslow thickness the correct cut-off point for performing sentinel node biopsy in patients with melanoma? Hell J Nucl Med, 2010, 13(3):253-256.
20. Schmidt CR, Panageas KS, Coit DG, Patel A, Brady MS. An increased number of sentinel lymph nodes is associated with advanced Breslow depth and lymphovascular invasion in patients with primary melanoma, Ann Surg Oncol, 2009, 16(4):948-952.
21. Sneyd MJ, Cox B. Clinical and histologic factors associated with melanoma thickness in New Zealand Europeans, Maori, and Pacific peoples, Cancer, 2010 Dec 14.
22. Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czerniecki B, Spitz F, Schuchter L, Elder D. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging, J Clin Oncol, 2004, 22(18): 3668-3676.
23. th edition, http://cancerstaging.org/staging/posters/melanoma8.5x11.pdf.
24. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification, J Clin Oncol, 2009, 27(36):6199-6206.
25. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma, J Clin Oncol, 2001, 19(16):3635-3648.
26. Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases, BMC Cancer, 2011, 11:85.
27. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma, J Cutan Pathol, 2005, 32(4):268-273.
28. Yonick DV, Ballo RM, Kahn E, Dahiya M, Yao K, Godellas C, Shoup M, Aranha GV. Predictors of positive sentinel lymph node in thin melanoma, Am J Surg, 2011, 201(3):324-327; discussion 327-328.
29. McMasters KM, Edwards MJ, Ross MI, Reintgen DS, Martin RC 2nd, Urist MM, Noyes RD, Sussman JJ, Stromberg AJ, Scoggins CR. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma, Ann Surg, 2010, 252(3):460-465; discussion 465-466.
30. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, Suter L. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer, 1999, 85(11):2391-2399.
31. Haass NK, Smalley KS, Herlyn M. The role of altered cell-cell communication in melanoma progression, J Mol Histol, 2004, 35(3):309-318.
32. Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, Essner R, Foshag LJ, Elashoff D, Morton DL. A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients, Cancer Invest, 2007, 25(5):285-293.
33. Day CL Jr, Lew RA, Harrist TJ. Malignant melanoma prognostic factors 4: ulceration width, J Dermatol Surg Oncol, 1984, 10(1):23-24.
34. Cochran AJ, Elashoff D, Morton DL, Elashoff R. Individualized prognosis for melanoma patients, Hum Pathol, 2000, 31(3):327-331.
35. Spatz A, Cook MG, Elder DE, Piepkorn M, Ruiter DJ, Barnhill RL. Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas, Eur J Cancer, 2003, 39(13):1861-1865.
36. Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, Colman MH, Zhang Y. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center, Cancer, 2003, 97(6):1488-1498.
37. Francken AB, Shaw HM, Thompson JF, Soong SJ, Accortt NA, Azzola MF, Scolyer RA, Milton GW, McCarthy WH, Colman MH, McGovern VJ. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up, Ann Surg Oncol, 2004, 11(4):426-433.
38. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC Jr, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database, J Clin Oncol, 2011, 29(16):2199-2205.
39. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma, J Clin Oncol, 2005, 23(31):8048-8056.
40. Murali R, Moncrieff MD, Hong J, Cooper CL, Shingde MV, Samuel DG, Thompson JF, Scolyer RA. The prognostic value of tumor mitotic rate and other clinicopathologic factors in patients with locoregional recurrences of melanoma, Ann Surg Oncol, 2010, 17(11):2992-2999.
41. Roach BA, Burton AL, Mays MP, Ginter BA, Martin RC, Stromberg AJ, Hagendoorn L, McMasters KM, Scoggins CR. Does mitotic rate predict sentinel lymph node metastasis or survival in patients with intermediate and thick melanoma? Am J Surg, 2010, 200(6):759-763; discussion 763-764.
42. Gimotty PA, Guerry D. Prognostication in thin cutaneous melanomas, Arch Pathol Lab Med, 2010, 134(12):1758-1763.
43. th edition, Protocol web posting date: February 1, 2011, http://www.cap.org/apps/docs/committees/cancer/cancer_protoco ls/2011/SkinMelanoma_11protocol.pdf.
44. th edition, http://www.cancerstaging.org/staging/posters/melanoma8.5x11.pdf.
45. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination, Am J Clin Pathol, 2007, 127(3):380-384.
46. Harrist TJ, Rigel DS, Day CL Jr, Sober AJ, Lew RA, Rhodes AR, Harris MN, Kopf AW, Friedman RJ, Golomb FM et al., "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness, Cancer, 1984, 53(10):2183-2187.
47. Cascinelli N, Bufalino R, Marolda R, Belli F, Nava M, Galluzzo D, Santinami M, Levene A. Regional non-nodal metastases of cutaneous melanoma, Eur J Surg Oncol, 1986, 12(2):175-180.
48. Rampen FH, Menzel S, Rümke P. Satellite and in-transit (SIT) metastases from melanoma are more predominant in females than in males, Anticancer Res, 1987, 7(3 Pt B):429-431.
49. De Giorgi V, Leporatti G, Massi D, Lo Russo G, Sestini S, Dini M, Lotti T. Outcome of patients with melanoma and histologically negative sentinel lymph nodes: one institution's experience, Oncology, 2007, 73(5-6):401-406.
50. Gutzmer R, Satzger I, Thoms KM, Völker B, Mitteldorf C, Kapp A, Bertsch HP, Kretschmer L. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas, J Dtsch Dermatol Ges, 2008, 6(3):198-203.
51. Li M, Zhang B, Sun B, Wang X, Ban X, Sun T, Liu Z, Zhao X. A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis, J Exp Clin Cancer Res, 2010, 29:109.
52. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, Al-Mehdi AB, Bernhard EJ, Muschel RJ. Apoptosis: an early event in metastatic inefficiency, Cancer Res, 2001, 61(1): 333-338.
53. Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd. Vascular involvement in the prognosis of primary cutaneous melanoma, Arch Dermatol, 2001, 137(9):1169-1173.
54. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival, Am J Pathol, 2003, 162(6):1951-1960.
55. Kashani-Sabet M, Shaikh L, Miller JR 3rd, Nosrati M, Ferreira CM, Debs RJ, Sagebiel RW. NF-kappa B in the vascular progression of melanoma, J Clin Oncol, 2004, 22(4):617-623.
56. Shea CR, Kline MA, Lugo J, McNutt NS. Angiotropic metastatic malignant melanoma, Am J Dermatopathol, 1995, 17(1):58-62.
57. Barnhill RL, Lugassy C. Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread, Pathology, 2004, 36(5):485-490.
58. Lugassy C, Barnhill RL. Angiotropic melanoma and extravascular migratory metastasis: a review, Adv Anat Pathol, 2007, 14(3):195-201.
59. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases, J Am Coll Surg, 1995, 181(3):193-201.
60. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis, Cancer, 1993, 72(10):3091-3098.
61. Elder DE, Guerry D 4th, VanHorn M, Hurwitz S, Zehngebot L, Goldman LI, LaRossa D, Hamilton R, Bondi EE, Clark WH Jr. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm), Cancer, 1985, 56(2):413-418.
62. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response, Lab Invest, 1996, 74(1):43-47.
63. van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, van den Eertwegh AJ, Hooijberg E, van Leeuwen PA, Meijer CJ, Oudejans JJ. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression, Int J Cancer, 2008, 123(3):609-615.
64. Burton AL, Roach BA, Mays MP, Chen AF, Ginter BA, Vierling AM, Scoggins CR, Martin RC, Stromberg AJ, Hagendoorn L, McMasters KM. Prognostic significance of tumor infiltrating lymphocytes in melanoma, Am Surg, 2011, 77(2):188-192.
65. Zettersten E, Shaikh L, Ramirez R, Kashani-Sabet M. Prognostic factors in primary cutaneous melanoma, Surg Clin North Am, 2003, 83(1):61-75.
66. Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal "thin" malignant melanoma. Identifying patients at risk, Ann Surg, 1988, 208(2):150-161.
67. Cecchi R, Pavesi M, Buralli L, Innocenti S, De Gaudio C. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas, Chir Ital, 2008, 60(2): 257-260.
68. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases, Arch Dermatol, 1987, 123(10):1326-1330.
69. Socrier Y, Lauwers-Cances V, Lamant L, Garrido I, Lauwers F, Lopez R, Rochaix P, Chevreau C, Payoux P, Viraben R, Paul C, Meyer N. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients, Br J Dermatol, 2010, 162(4):830-834.
70. Holzmann B, Bröcker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmüller G, Johnson JP. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes, Int J Cancer, 1987, 39(4):466-471.
71. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma, N Engl J Med, 2005, 353(20):2135-2147.
72. van 't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL. N-ras mutations in human cutaneous melanoma from sun-exposed body sites, Mol Cell Biol, 1989, 9(7):3114-3116.
73. Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt NS, Bressler J, Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype, Oncogene, 1989, 4(11):1363-1374.
74. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutations in human melanoma: a marker of malignant progression, J Invest Dermatol, 1994, 102(3): 285-290.
75. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer, Nature, 2002, 417(6892):949-954.
76. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma, Oncogene, 2006, 25(24):3357-3364.
77. Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity, Cancer Res, 2006, 66(13):6503-6511.
78. Bataille V. Genetics of familial and sporadic melanoma, Clin Exp Dermatol, 2000, 25(6):464-470.
79. Halaban R. Rb/E2F: a two-edged sword in the melanocytic system, Cancer Metastasis Rev, 2005, 24(2):339-356.
80. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Main roads to melanoma, J Transl Med, 2009, 7:86.
81. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, Shrager J. A melanoma molecular disease model, PLoS One, 2011, 6(3):e18257.
82. Bauer J, Büttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, Scolyer RA, Bastian BC. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site, Pigment Cell Melanoma Res, 2011, 24(2):345-351.
83. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS. High frequency of BRAF mutations in nevi, Nat Genet, 2003, 33(1):19-20.
84. Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas, Pigment Cell Melanoma Res, 2010, 23(6):820-827.
85. Vultur A, Villanueva J, Herlyn M. BRAF inhibitor unveils its potential against advanced melanoma, Cancer Cell, 2010, 18(4):301-302.
86. Dienstmann R, Tabernero J. BRAF as a target for cancer therapy, Anticancer Agents Med Chem, 2011, 11(3):285-295.
87. Li J, Xu M, Yang Z, Li A, Dong J. Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells, Cancer Invest, 2010, 28(4):350-356.
88. Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma, J Invest Dermatol, 2010, 130(1):20-27.
89. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent, Melanoma Res, 1998, 8(1):17-23.
90. Li G, Bush JA, Ho VC. p53-dependent apoptosis in melanoma cells after treatment with camptothecin, J Invest Dermatol, 2000, 114(3):514-519.
91. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC. Improving melanoma classification by integrating genetic and morphologic features, PLoS Med, 2008, 5(6):e120.
92. Broekaert SM, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C, Barnhill RL, Busam KJ, Cochran AJ, Cook MG, Elder DE, McCarthy SW, Mihm MC, Schadendorf D, Scolyer RA, Spatz A, Bastian BC. Genetic and morphologic features for melanoma classification, Pigment Cell Melanoma Res, 2010, 23(6):763-770.
93. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer. Gene expression profiling of primary cutaneous melanoma and clinical outcome, J Natl Cancer Inst, 2006, 98(7):472-482.
94. Winnepenninckx V, Van den Oord JJ. Gene expression profiling of primary cutaneous melanoma, Verh K Acad Geneeskd Belg, 2007, 69(1):23-45.
95. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, Lonardi S, Zavadil J, Osman I, Bhardwaj N. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival, Proc Natl Acad Sci U S A, 2009, 106(48):20429-20434.
96. Lugassy C, Lazar V, Dessen P, van den Oord JJ, Winnepenninckx V, Spatz A, Bagot M, Bensussan A, Janin A, Eggermont AM, Barnhill RL. Gene expression profiling of human angiotropic primary melanoma: selection of 15 differentially expressed genes potentially involved in extravascular migratory metastasis, Eur J Cancer, 2011, 47(8):1267-1275.
97. Alonso SR, Tracey L, Ortiz P, Pérez-Gómez B, Palacios J, Pollán M, Linares J, Serrano S, Sáez-Castillo AI, Sánchez L, Pajares R, Sánchez-Aguilera A, Artiga MJ, Piris MA, Rodríguez-Peralto JL. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis, Cancer Res, 2007, 67(7):3450-3460.
98. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma, J Invest Dermatol, 2006, 126(2):422-431.
99. Conway K, Edmiston SN, Khondker ZS, Groben PA, Zhou X, Chu H, Kuan PF, Hao H, Carson C, Berwick M, Olilla DW, Thomas NE. DNA-methylation profiling distinguishes malignant melanomas from benign nevi, Pigment Cell Melanoma Res, 2011, 24()2:352-360.
100. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma, J Clin Oncol, 2006, 24(26):4340-4346.
101. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma, Int J Cancer, 1997, 74(5):535-539.
102. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma, J Pathol, 1998, 186(1):51-58.
103. Niezabitowski A, Czajecki K, Ryś J, Kruczak A, Gruchała A, Wasilewska A, Lackowska B, Sokołowski A, Szklarski W. Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study, J Surg Oncol, 1999, 70(3):150-160.
104. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas, Hum Pathol, 1999, 30(3):339-344.
105. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma, Clin Cancer Res, 2000, 6(5):1845-1853.
106. Ferrier CM, Suciu S, Van Geloof WL, Straatman H, Eggermont AM, Koops HS, Kroon BB, Lejeune FJ, Kleeberg UR, van Muijen GN, Ruiter DJ. High tPAexpression in primary melanoma of the limb correlates with good prognosis, Br J Cancer, 2000, 83(10):1351-1359.
107. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, Das Gupta TK. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma, Cancer Res, 2000, 60(18):5012-5016.
108. Karjalainen JM, Tammi RH, Tammi MI, Eskelinen MJ, Agren UM, Parkkinen JJ, Alhava EM, Kosma VM. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma, Am J Pathol, 2000, 157(3):957-965.
109. Flørenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R. Cyclin A expression in superficial spreading melanoma correlates with clinical outcome, J Pathol, 2001, 195(5):530-536.
110. Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L, Acuña MJ, Pajares R, Martínez-Tello FJ, Hortelano CM, Piris MA, Rodríguez-Peralto JL. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study, Am J Pathol, 2004, 164(1):193-203.
111. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis, J Natl Cancer Inst, 2009, 101(7):452-474.
112. Korabiowska M, Tscherny M, Stachura J, Berger H, Cordon-Cardo C, Brinck U. Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression, Mod Pathol, 2002, 15(4):426-433.
113. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma, Clin Cancer Res, 2005, 11(5): 1835-1841.
114. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker, Plast Reconstr Surg, 2005, 115(2):367-375.
115. Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, Zelger B. Met allothionein-overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients, Br J Cancer, 2006, 94(6):835-841.
116. Weinlich G, Topar G, Eisendle K, Fritsch PO, Zelger B. Comparison of met allothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma, J Eur Acad Dermatol Venereol, 2007, 21(5):669-677.
117. Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, Leong SP, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma, J Clin Oncol, 2006, 24(28):4565-4569.
118. Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma, J Clin Oncol, 1998, 16(11):3584-3591.
119. Pearl RA, Pacifico MD, Richman PI, Wilson GD, Grover R. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy, J Plast Reconstr Aesthet Surg, 2008, 61(3):265-271.
120. Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma, Cancer Res, 2004, 64(23):8773-8777.
121. Hofbauer GF, Burkhart A, Schüler G, Dummer R, Burg G, Nestle FO. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma, J Immunother, 2004, 27(1):73-78.
122. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction, Cancer Res, 2005, 65(23):11185-11192.
123. Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival, Cancer Res, 2003, 63(23):8103-8107.
124. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M. Osteopontin as a molecular prognostic marker for melanoma, Cancer, 2008, 112(1):144-150.
125. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients, Int J Cancer, 2006, 119(4):861-866.
126. Väisänen AH, Kallioinen M, Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix met alloproteinases 2 and 9 in cutaneous melanoma, Hum Pathol, 2008, 39(3):377-385.
127. Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas, Nature, 1980, 286(5771):400-401.
128. Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y. Immunohistochemical demonstration of S100 protein in human malignant melanoma and pigmented nevi, Gann, 1981, 72(2):335-336.
129. Gaynor R, Herschman HR, Irie R, Jones P, Morton D, Cochran A. S100 protein: a marker for human malignant melanomas? Lancet, 1981, 1(8225):869-871.
130. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D. Clinical significance of serum S100 in metastatic malignant melanoma, Eur J Cancer, 1995, 31A(11):1898-1902.
131. Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma, Br J Dermatol, 1997, 137(3):381-385.
132. Henze G, Dummer R, Joller-Jemelka HI, Böni R, Burg G. Serum S100-a marker for disease monitoring in metastatic melanoma, Dermatology, 1997, 194(3):208-212.
133. Buer J, Probst M, Franzke A, Duensing S, Haindl J, Volkenandt M, Wittke F, Hoffmann R, Ganser A, Atzpodien J. Elevated serum levels of S100 and survival in metastatic malignant melanoma, Br J Cancer, 1997, 75(9): 1373-1376.
134. Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, Christophers E. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma, Oncology, 1999, 56(4):338-344.
135. Hamberg AP, Korse CM, Bonfrer JM, de Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma, Melanoma Res, 2003, 13(1):45-49.
136. Egberts F, Hitschler WN, Weichenthal M, Hauschild A. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse, Melanoma Res, 2009, 19(1):31-35.
137. Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, Kerst JM, Nieweg OE, de Gast GC. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients, Eur J Cancer, 2005, 41(3):386-392.
138. Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma, Br J Dermatol, 2000, 143(2):269-274.
139. Dummer R, Panizzon R, Bloch PH, Burg G; Task Force Skin Cancer. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma, Dermatology, 2005, 210(1):39-44.
140. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma, Melanoma Res, 2007, 17(6):393-399.
141. Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R, Hauschild A. Short German guidelines: malignant melanoma, J Dtsch Dermatol Ges, 2008, 6(Suppl 1):S9-S14.
142. Acland K, Evans AV, Abraha H, Healy CM, Roblin P, Calonje E, Orchard G, Higgins E, Sherwood R, Russell-Jones R. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma, Br J Dermatol, 2002, 146(5):832-835.
143. Egberts F, Momkvist A, Egberts JH, Kaehler KC, Hauschild A. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients, Anticancer Res, 2010, 30(5):1799-1805.
144. Hill BR, Levi C. Elevation of a serum component in neoplastic disease, Cancer Res, 1954, 14(7):513-515.
145. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS. Prognostic factors for survival of patients treated systemically for disseminated melanoma, J Clin Oncol, 1998, 16(3):1103-1111.
146. Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AM. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951), Eur J Cancer, 2009, 45(10):1807-1814.
147. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC Jr, Slominski A. Current concepts of metastasis in melanoma, Expert Rev Dermatol, 2008, 3(5):569-585.
148. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma, Cancer, 1983, 51(5):840-843.
149. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, Martin R. Autocrine tumor cell growth-inhibiting activities from human malignant melanoma, Cancer Res, 1989, 49(19):5358-5363.
150. Apfel R, Lottspeich F, Hoppe J, Behl C, Dürr G, Bogdahn U. Purification and analysis of growth regulating proteins secreted by a human melanoma cell line, Melanoma Res, 1992, 2(5-6):327-336.
151. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U. Cloning of a novel malignant melanomaderived growth-regulatory protein, MIA, Cancer Res, 1994, 54(21):5695-5701.
152. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma, Cancer Res, 1997, 57(15):3149-3153.
153. Krähn G, Kaskel P, Sander S, Waizenhöfer PJ, Wortmann S, Leiter U, Peter RU. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase, Anticancer Res, 2001, 21(2B): 1311-1316.
154. Mouawad R, Spano JP, Khayat D. Old and new serological biomarkers in melanoma: where we are in 2009, Melanoma Res, 2010, 20(2):67-76.
155. Greco M, Mitri MD, Chiriacò F, Leo G, Brienza E, Maffia M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity, Cancer Lett, 2009, 283(2):222-229.
156. Solassol J, Guillot B, Maudelonde T. Circulating prognosis markers in melanoma: proteomic profiling and clinical studies, Ann Biol Clin (Paris), 2011, 69(2):151-157.
157. Garnier JP, Letellier S, Cassinat B, Lebbé C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B, Stoitchkov K, Le Bricon T. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma, Eur J Cancer, 2007, 43(4):816-821.